Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Capital Expenditures (2022 - 2023)

Spruce Biosciences (SPRB) has disclosed Capital Expenditures for 2 consecutive years, with $7000.0 as the latest value for Q3 2023.

  • Quarterly Capital Expenditures rose 250.0% to $7000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Dec 2024, down 22.22% year-over-year, with the annual reading at $7000.0 for FY2023, 12.5% down from the prior year.
  • Capital Expenditures for Q3 2023 was $7000.0 at Spruce Biosciences, up from $2000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $7000.0 in Q3 2023, with the low at $2000.0 in Q3 2022.